These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 23658850)

  • 1. Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison.
    Cota GF; de Sousa MR; Fereguetti TO; Rabello A
    PLoS Negl Trop Dis; 2013; 7(5):e2195. PubMed ID: 23658850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group.
    Laguna F; López-Vélez R; Pulido F; Salas A; Torre-Cisneros J; Torres E; Medrano FJ; Sanz J; Picó G; Gómez-Rodrigo J; Pasquau J; Alvar J
    AIDS; 1999 Jun; 13(9):1063-9. PubMed ID: 10397536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serious adverse events following treatment of visceral leishmaniasis: A systematic review and meta-analysis.
    Singh-Phulgenda S; Dahal P; Ngu R; Maguire BJ; Hawryszkiewycz A; Rashan S; Brack M; Halleux CM; Alves F; Stepniewska K; Olliaro PL; Guerin PJ
    PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009302. PubMed ID: 33780461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of leishmaniasis in HIV-positive patients.
    Laguna F
    Ann Trop Med Parasitol; 2003 Oct; 97 Suppl 1():135-42. PubMed ID: 14678640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil.
    Borges MM; Pranchevicius MC; Noronha EF; Romero GA; Carranza-Tamayo CO
    Rev Soc Bras Med Trop; 2017; 50(1):67-74. PubMed ID: 28327804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review.
    Brito NC; Rabello A; Cota GF
    PLoS One; 2017; 12(9):e0184777. PubMed ID: 28926630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil: A multicenter, randomized, open label trial.
    Romero GAS; Costa DL; Costa CHN; de Almeida RP; de Melo EV; de Carvalho SFG; Rabello A; de Carvalho AL; Sousa AQ; Leite RD; Lima SS; Amaral TA; Alves FP; Rode J;
    PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005706. PubMed ID: 28662034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B.
    Morizot G; Jouffroy R; Faye A; Chabert P; Belhouari K; Calin R; Charlier C; Miailhes P; Siriez JY; Mouri O; Yera H; Gilquin J; Tubiana R; Lanternier F; Mamzer MF; Legendre C; Peyramond D; Caumes E; Lortholary O; Buffet P
    PLoS Negl Trop Dis; 2016 Jan; 10(1):e0004304. PubMed ID: 26735920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study.
    Laguna F; Videla S; Jiménez-Mejías ME; Sirera G; Torre-Cisneros J; Ribera E; Prados D; Clotet B; Sust M; López-Vélez R; Alvar J;
    J Antimicrob Chemother; 2003 Sep; 52(3):464-8. PubMed ID: 12888588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
    Ritmeijer K; ter Horst R; Chane S; Aderie EM; Piening T; Collin SM; Davidson RN
    Clin Infect Dis; 2011 Dec; 53(12):e152-8. PubMed ID: 22016502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphotericin B for treatment of visceral leishmaniasis: systematic review and meta-analysis of prospective comparative clinical studies including dose-ranging studies.
    Rodrigo C; Weeratunga P; Fernando SD; Rajapakse S
    Clin Microbiol Infect; 2018 Jun; 24(6):591-598. PubMed ID: 29138100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis.
    Gebreyohannes EA; Bhagvathula AS; Abegaz TM; Seid MA
    Infect Dis Poverty; 2018 Oct; 7(1):108. PubMed ID: 30340519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leishmania-HIV co-infection: clinical presentation and outcomes in an urban area in Brazil.
    Cota GF; de Sousa MR; de Mendonça AL; Patrocinio A; Assunção LS; de Faria SR; Rabello A
    PLoS Negl Trop Dis; 2014 Apr; 8(4):e2816. PubMed ID: 24743472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of liposomal amphotericin B for treatment of complicated visceral leishmaniasis in patients without HIV, North-West Ethiopia.
    Tamiru A; Tigabu B; Yifru S; Diro E; Hailu A
    BMC Infect Dis; 2016 Oct; 16(1):548. PubMed ID: 27724891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of an unsatisfactory response to pentavalent antimony in the treatment of American visceral leishmaniasis.
    Santos MA; Marques RC; Farias CA; Vasconcelos DM; Stewart JM; Costa DL; Costa CH
    Rev Soc Bras Med Trop; 2002; 35(6):629-33. PubMed ID: 12612746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal amphotericin B versus pentavalent antimony salts for visceral Leishmania in children.
    Apa H; Devrim İ; Bayram N; Deveci R; Demir-Özek G; Cartı ÖU
    Turk J Pediatr; 2013; 55(4):378-83. PubMed ID: 24292030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The initial effectiveness of liposomal amphotericin B (AmBisome) and miltefosine combination for treatment of visceral leishmaniasis in HIV co-infected patients in Ethiopia: A retrospective cohort study.
    Abongomera C; Diro E; de Lima Pereira A; Buyze J; Stille K; Ahmed F; van Griensven J; Ritmeijer K
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006527. PubMed ID: 29799869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.
    Minodier P; Retornaz K; Horelt A; Garnier JM
    Fundam Clin Pharmacol; 2003 Apr; 17(2):183-8. PubMed ID: 12667228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
    Delgado J; Macías J; Pineda JA; Corzo JE; González-Moreno MP; de la Rosa R; Sánchez-Quijano A; Leal M; Lissen E
    Am J Trop Med Hyg; 1999 Nov; 61(5):766-9. PubMed ID: 10586909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
    Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
    Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.